22 May 2013
Keywords: Geron, Angiochem, License, Peptide technology, GRN1005, Brain cancer
Article | 07 December 2010
California, USA-based Geron Corp (Nasdaq: GERN) has entered into an agreement with privately held Canadian firm Angiochem for a worldwide ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 December 2010
6 December 2010
8 December 2010
© 2013 thepharmaletter.com